MYC and chronic kidney disease: Oral administration of an Myc inhibitor can significantly reduce KIM-1 expression, which is a sensitive indicator of renal tubular injury, the accumulation of inflammation in mice, and fibrosis, while ultimately slowing the progression of AKI to CKD (Lemos et al., 2018).